Zhihu Inc. Files Its 2025 Annual Report on Form 20-F

BEIJING, China, April 17, 2026 (GLOBE NEWSWIRE) — Zhihu Inc. (“Zhihu” or the “Company”) (NYSE: ZH; HKEX: 2390), a leading online content community in China, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the Securities and Exchange Commission on April 17, 2026. The annual report can be accessed on the Company’s investor relations website at https://ir.zhihu.com.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Investor Relations, Zhihu Inc., 18 Xueqing Road, Haidian District, Beijing 100083, People’s Republic of China.

About Zhihu Inc.

Zhihu Inc. (NYSE: ZH; HKEX: 2390) is a leading online content community where people come to find solutions, make decisions, seek inspiration, and have fun. Since the initial launch in 2010, Zhihu has grown into the largest Q&A-inspired online content community in China. For more information, please visit https://ir.zhihu.com.

For investor and media inquiries, please contact:

Zhihu Inc.
Email: [email protected] 

Christensen Advisory
Roger Hu
Tel: +86-10-5900-1548
Email: [email protected]



AOI Expands Its Houston-Area Footprint to 900,000 Square Feet to Increase Capacity and Support Future Growth

SUGAR LAND, Texas, April 17, 2026 (GLOBE NEWSWIRE) — Applied Optoelectronics, Inc. (NASDAQ: AAOI), a leading provider of advanced optical and HFC networking products powering AI, today announced plans to expand its Houston-area footprint through the addition of two adjacent buildings in Pearland, Texas, adding approximately 388,000 square feet of manufacturing capacity.

The expansion builds on AOI’s existing U.S. operations, which include a 210,000-square-foot manufacturing facility currently under development near its Sugar Land headquarters, where the company operates 135,000 square feet of capacity, as well as a recently leased 154,000-square-foot building at Blue Ridge Commerce Center.

“The demand for optical connectivity in data centers has exceeded our expectations,” said Dr. Thompson Lin, Founder, Chairman, and CEO of AOI. “We are focused on ensuring every critical function—from supply chain and manufacturing capacity to quality, reliability, and customer support—is positioned to scale rapidly to meet this demand. With the acquisition of these properties, we will have the footprint to expand our capacity to produce up to 700,000 units of 800G and 1.6T transceivers per month in the Houston area, while also expanding our laser fabrication capacity by around 350% by the end of 2027.”

“This expansion is aligned with the 2027 capacity targets we outlined on our most recent earnings call and represents the next step in our strategy to become the premier high-volume U.S. producer of AI-focused data center transceivers and optics,” said Dr. Stefan Murry, Chief Financial Officer and Chief Strategy Officer. “By expanding our footprint now, we are ensuring we can meet accelerating customer demand and support the next wave of AI infrastructure deployments.”

Additional Resources:

About AOI  
Applied Optoelectronics, Inc. (AOI) is a leading developer and manufacturer of advanced optical and HFC networking products that are the building blocks for AI datacenters, CATV and broadband fiber access networks around the world. AOI supplies this critical infrastructure to tier-one customers across cloud computing, CATV broadband, telecom, and FTTH markets. The company has R&D facilities in Atlanta, GA, and engineering and manufacturing facilities at its corporate headquarters in Sugar Land, TX, as well as in Taipei, Taiwan and Ningbo, China. For additional information, visit www.ao-inc.com.  

Media contact:
Sara Cicero
[email protected]
770-331-0269



BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

Live event to be held on Thursday, April 23, at 2:00 p.m. ET 

Company focused on advancing launch strategy ahead of November 14 PDUFA target action date

NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced it will host a virtual event on Thursday, April 23, from 2:00 to 3:00 p.m. ET. 

The event will center on the Company’s ongoing launch strategy initiatives ahead of the November 14 PDUFA target action date of IGALMI® for the treatment of acute agitation associated with bipolar disorders and schizophrenia in the at-home setting. A presentation by Mark Pavao, the Company’s Interim Chief Commercial Officer, will outline key elements of the Company’s commercial launch plan, building on insights from the recently completed market opportunity assessment. Analyses from the assessment identified up to 86 million addressable annual episodes of acute agitation in the at-home setting in the United States, underscoring the substantial market opportunity for IGALMI. 

The event will be moderated by Michael King, Managing Director at Rodman & Renshaw and covering analyst for BioXcel Therapeutics.

Webcast Details: 

To register for the webcast, click here. A replay of the event will be available on the BioXcel Therapeutics website following the live presentation.  

Attendees may submit questions via written Q&A during the event. Attendees are encouraged to log in approximately 10 minutes prior to the scheduled start time.  

About IGALMI

®

 (dexmedetomidine) sublingual film

INDICATION

IGALMI® (dexmedetomidine) sublingual film is a prescription medicine, administered under the supervision of a health care provider, that is placed under the tongue or behind the lower lip and is used for the acute treatment of agitation associated with schizophrenia and bipolar disorder I or II in adults. The safety and effectiveness of IGALMI has not been studied beyond 24 hours from the first dose. It is not known if IGALMI is safe and effective in children.

IMPORTANT SAFETY INFORMATION 

IGALMI can cause serious side effects, including: 

  • Decreased blood pressure, low blood pressure upon standing, and slower than normal heart rate, which may be more likely in patients with low blood volume, diabetes, chronic high blood pressure, and older patients. IGALMI is taken under the supervision of a healthcare provider who will monitor vital signs (like blood pressure and heart rate) and alertness after IGALMI is administered to help prevent falling or fainting. Patients should be adequately hydrated and sit or lie down after taking IGALMI and instructed to tell their healthcare provider if they feel dizzy, lightheaded, or faint. 
  • Heart rhythm changes (QT interval prolongation). IGALMI should not be given to patients with an abnormal heart rhythm, a history of an irregular heartbeat, slow heart rate, low potassium, low magnesium, or taking other drugs that could affect heart rhythm. Taking IGALMI with a history of abnormal heart rhythm can increase the risk of torsades de pointes and sudden death. Patients should be instructed to tell their healthcare provider immediately if they feel faint or have heart palpitations. 
  • Sleepiness/drowsiness. Patients should not perform activities requiring mental alertness, such as driving or operating hazardous machinery, for at least 8 hours after taking IGALMI. 
  • Withdrawal reactions, tolerance, and decreased response/efficacy. IGALMI was not studied for longer than 24 hours after the first dose. Physical dependence, withdrawal symptoms (e.g., nausea, vomiting, agitation), and decreased response to IGALMI may occur if IGALMI is used longer than 24 hours. 

The most common side effects of IGALMI in clinical studies were sleepiness or drowsiness, a prickling or tingling sensation or numbness of the mouth, dizziness, dry mouth, low blood pressure, and low blood pressure upon standing. 

These are not all the possible side effects of IGALMI. Patients should speak with their healthcare provider for medical advice about side effects. 

Patients should tell their healthcare provider about their medical history, including if they suffer from any known heart problems, low potassium, low magnesium, low blood pressure, low heart rate, diabetes, high blood pressure, history of fainting, or liver impairment. They should also tell their healthcare provider if they are pregnant or breastfeeding or take any medicines, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Patients should especially tell their healthcare provider if they take any drugs that lower blood pressure, change heart rate, or take anesthetics, sedatives, hypnotics, and opioids. 

Everyone is encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You can also contact BioXcel Therapeutics, Inc. at 1-833-201-1088 or [email protected]

Please see full prescribing information at Igalmi.com. 

About BXCL501

Outside of its approved indication by the U.S. Food and Drug Administration as IGALMI® (dexmedetomidine) sublingual film, BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist. BXCL501 is under investigation by BioXcel Therapeutics for the acute treatment of agitation associated with Alzheimer’s dementia and for the acute treatment of agitation associated with bipolar I or II disorder or schizophrenia in the at-home setting. The safety and efficacy of BXCL501 for these investigational uses have not been established. BXCL501 has been granted Breakthrough Therapy designation by the FDA for the acute treatment of agitation associated with dementia and Fast Track designation for the acute treatment of agitation associated with schizophrenia, bipolar disorders, and dementia.

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience. Its wholly owned subsidiary, OnkosXcel Therapeutics, is focused on the development of medicines in immuno-oncology. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indications. For more information, please visit bioxceltherapeutics.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release other than statements of historical fact should be considered forward-looking statements, including, without limitation, statements related to: the approval of IGALMI for use in the at-home setting; bringing IGALMI® directly to patients in the at-home setting; the approval of IGALMI for use in the at-home setting; bringing IGALMI® directly to patients in the at-home setting; use of IGALMI in approximately 70% of schizophrenia and bipolar disorder patients, regardless of agitation severity; prescribers using IGALMI either alone or in combination with existing off-label treatments for acute agitation; IGALMI replacing benzodiazepines, which may cause dependence; broad formulary coverage of IGALMI with standard adjudication controls; patients with schizophrenia and bipolar disorder using IGALMI in approximately 80% of their acute agitation episodes; evaluating go-to-market options; reimagining existing medicines and accelerating the development of innovative therapies; transforming the standard of care in neuropsychiatry and improve lives around the world. When used herein, words including “anticipate,” “believe,” “can,” “continue,” “could,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements use these words or expressions. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; the impact of the reprioritization; its significant indebtedness, ability to comply with covenant obligations and potential payment obligations related to such indebtedness and other contractual obligations; the Company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern; its limited experience in drug discovery and drug development; risks related to the TRANQUILITY program; its dependence on the success and commercialization of IGALMI®, BXCL501, BXCL502, BXCL701 and BXCL702 and other product candidates; the number of episodes of agitation and the size of the Company’s total addressable market may be overestimated, and approval that the Company may obtain may be based on a narrower definition of the patient population; its lack of experience in marketing and selling drug products; the risk that IGALMI® or the Company’s product candidates may not be accepted by physicians or the medical community in general; the Company still faces extensive and ongoing regulatory requirements and obligations for IGALMI®; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; undesirable side effects caused by the Company’s product candidates; its novel approach to the discovery and development of product candidates based on EvolverAI; the significant influence of and dependence on BioXcel LLC; its exposure to patent infringement lawsuits; its reliance on third parties; its ability to comply with the extensive regulations applicable to it; impacts from data breaches or cyber-attacks, if any; risks associated with the increased scrutiny relating to environmental, social and governance (ESG) matters; risks associated with federal, state or foreign health care “fraud and abuse” laws; and its ability to commercialize its product candidates, as well as the important factors discussed under the caption “Risk Factors” in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at and the Investors section of the Company’s website at. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this press release.

Contact Information: 

Corporate/Investors 
Russo Partners 
Nic Johnson 
[email protected]  
1.303.482.6405 

Media 
Russo Partners 
David Schull 
[email protected]  
1.858.717.2310 

Source: BioXcel Therapeutics, Inc. 



Intchains Group Limited Provides Staking Activities Update; Advances Strategic Transformation with AI-Enabled Operating Model to Enhance Efficiency and Productivity

SINGAPORE, April 17, 2026 (GLOBE NEWSWIRE) — Intchains Group Limited (Nasdaq: ICG) (“we,” or the “Company”), a company focuses on the development of altcoin mining products, the strategic acquisition, holding, and staking of Ethereum-based cryptocurrencies, and the delivery of Web3 infrastructure services through the operation of a Proof-of-Stake cryptocurrency staking platform, today provided an update on its Ethereum (“ETH”) staking activities, and announced the advancement of its strategic transformation through the adoption of an AI-enabled operating model.

Accelerating ETH Staking: Over 8,000 ETH Actively Staked on FalconX and Goldshell Stake

Since mid-2025, Intchains has initiated ETH staking activities to generate incremental returns from idle treasury assets. In 2026, Intchains continued to accelerate ETH staking, by progressively staking the bulk of its ETH treasury holdings.

As of April 16, 2026, Intchains had staked a total of 8,040 ETH owned by the Company. Of this amount, 1,000 has been staked on the FalconX platform, 7,040 ETH on its proprietary Goldshell Stake platform. In addition, 1,363 ETH has been staked on its proprietary Goldshell Stake by third parties. By utilizing a multi-platform staking strategy, Intchains enhances diversification across its ETH holdings, aiming to maximize returns while effectively mitigating risk.

Mr. Qiang Ding, Chairman of the Board of Directors and Chief Executive Officer, commented, “Our ETH strategy is long-term, value-based and sustainable. With a leading ETH treasury holding position, we are proactively taking steps to unlock the potential value of these digital assets by increasing staking activities to drive incremental returns. As we continue to accumulate ETH through a prudent and opportunistic approach, we believe our multi-platform, risk-adjusted staking strategy will create additional revenue opportunities for us.”

Strategic Transformation with AI-Enabled Operating Model

Intchains’ new AI initiative is designed to position the Company for its next phase of development through a fundamental redesign of workflows, operating processes, and organizational structure. At the core of this transformation is a deliberate shift toward an AI-enabled operating model. Intchains is actively integrating advanced automation and intelligent tools across key functions to redesign how work is performed, streamlining processes, reducing friction in execution, and enabling faster, data-driven decision-making.

Key areas where AI-enabled tools and automation have been deployed include:

  • Chip & Product R&D
  • Sales and marketing efforts
  • Overall business operations

As part of this broader initiative, the Company has also implemented cost-management measures aimed at optimizing headcount and establishing a leaner, more efficient cost structure. Following the divestiture of non-core activities completed late last year, Intchains has already reduced its total headcount by approximately 20% as compared to headcount at the start of 2026, reflecting an initial phase of organizational simplification and increased strategic focus.

As these initiatives scale, the Company currently expects to further streamline its organizational structure, targeting an aggregate reduction in its total workforce of approximately 35% as compared to the level at the start of 2026, driven not only by structural efficiencies but also by the replacement of manual, repetitive workflows with technology-enabled solutions. The Company estimates that these efforts will translate into annualized labor cost savings of over approximately RMB20 million, subject to final validation and implementation timing.

Commenting on the Company’s AI strategy, Mr. Qiang Ding continued, “We are at a defining inflection point, not just resizing our business, but reinventing it. By embedding AI and automation, we are establishing a more efficient, agile, and intelligent organization. Focusing on core mining technologies, advancing our Ethereum strategy, strengthening operational discipline and R&D focus, allows us to sharpen execution, enhance operating cost management, and improve efficiencies across the organization. This transformation creates a leaner structure, supports sustainable margin expansion, and positions us to adapt, execute, and innovate through 2026 and beyond. As we continue to invest in R&D, supported by AI-powered insights, we expect to launch new mining products in the second half of 2026 (subject to market conditions and development progress), and are well positioned to seize market opportunities as they arise.”

Strategic Direction

Looking ahead, Intchains will continue to expand the application of AI-driven tools across its operations, with a focus on standardization, scalability, and continuous improvement. The Company believes that a leaner organizational structure, combined with technology-enabled execution, will enhance its long-term competitiveness and support sustainable value creation.

This transformation is expected to unfold progressively, with ongoing evaluation to ensure alignment between operational efficiency, business performance, and strategic priorities.

About Intchains Group Limited

Intchains Group Limited focuses on the development of altcoin mining products, the strategic acquisition, holding, and staking of Ethereum-based cryptocurrencies, and the delivery of Web3 infrastructure services through the operation of a Proof-of-Stake cryptocurrency staking platform. For more information, please visit the Company’s website at: https://intchains.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Forward-looking statements include, but are not limited to, statements about: (i) our goals and strategies; (ii) our future business development, financial condition and results of operations; (iii) expected changes in our revenue, costs or expenditures; (iv) growth of and competition trends in our industry; (v) our expectations regarding demand for, and market acceptance of, our products; (vi) general economic and business conditions in the markets in which we operate; (vii) relevant government policies and regulations relating to our business and industry; (viii) fluctuations in the market price of ETH-based cryptocurrencies; gains or losses from the sale of ETH-based cryptocurrencies; changes in accounting treatment for the Company’s ETH-based cryptocurrencies holdings; a decrease in liquidity in the markets in which ETH-based cryptocurrencies are traded; security breaches, cyberattacks, unauthorized access, loss of private keys, fraud, or other events leading to the loss of the Company’s ETH-based cryptocurrencies; impacts to the price and rate of adoption of ETH-based cryptocurrencies associated with financial difficulties and bankruptcies of various participants in the industry; and (ix) assumptions underlying or related to any of the foregoing. Investors can identify these forward-looking statements by words or phrases such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For investor and media inquiries, please contact:

Intchains Group Limited

Investor relations
Email: [email protected]

The Equity Group

Lena Cati, Senior Vice President
212-836-9611 / [email protected]

Alice Zhang, Associate
212-836-9610 / [email protected]    



USA Rare Earth Appoints Chaitan Kansal as Chief Commercial Officer

Seasoned Critical Minerals and Specialty Chemicals Executive to Drive Commercial Strategy Across USA Rare Earth’s Integrated Value Chain

STILLWATER, Okla., April 17, 2026 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (the “Company”) today announced the appointment of Chaitan Kansal as Chief Commercial Officer. In this newly created role, Kansal will oversee the Company’s global commercial strategy, including customer engagement, market development, offtake agreements, pricing, and go-to-market execution across the Company’s integrated mine-to-magnet platform.

An experienced industry leader, Kansal joins USA Rare Earth at a significant inflection point as the Company accelerates execution across its global value chain. The Company recently announced the commission of Phase 1a commercial magnet production at its Stillwater, Oklahoma facility, as well as a strategic investment in Carester SAS, a leading French rare earth separation and processing company. These milestones mark USA Rare Earth’s transition from development to active production, signaling the need for dedicated go-to-market leadership to capture the significant commercial opportunities ahead.

“As USA Rare Earth transitions from development to commercialization, Chaitan’s appointment reflects the strategic importance we place on building world-class commercial capabilities,” said Barbara Humpton, CEO of USA Rare Earth. “His deep experience across lithium, battery materials, and specialty chemicals — combined with a track record of executing go-to-market strategies at global scale — makes him the ideal leader to drive customer engagement, secure long-term offtake partnerships, and position the Company as the partner of choice for rare earth products across the Western world.”

“I am thrilled to join USA Rare Earth at such a pivotal moment in the Company’s trajectory,” said Kansal. “The opportunity to build a commercial engine for the leading global fully integrated rare earth value chain is extraordinary. I look forward to working with the team to develop the customer relationships and market strategies that will underpin the Company’s long-term growth and support our national security and allied supply chain objectives.”

Kansal brings more than 25 years of experience across the critical minerals, specialty chemicals, and advanced materials sectors. Most recently, he served as Chief Commercial Officer at Ecobat, a global leader in battery recycling and lead production, where he drove strategic growth initiatives across the company’s international portfolio. Prior to Ecobat, Kansal served as Chief Marketing Officer at Albemarle Corporation, where he led the Energy Storage Global Business Unit Growth Platforms, developing and executing a comprehensive lithium go-to-market strategy during a period of rapid market expansion. Earlier in his career, Kansal spent seven years at Eastman Chemical Company, holding increasingly senior roles, including Global General Manager of the Specialty Fluids & Energy division, Global Business Director for Adhesive Resins, and Director of Corporate Strategy. He also served as Director of Strategy at Ashland Inc. and spent seven years as a management consultant at Kearney (formerly A.T. Kearney). Kansal began his career as an Engineering Team Lead and Senior Software Design Engineer at MicroStrategy Inc.

Kansal holds an MBA in Corporate Strategy and Finance from the Stephen M. Ross School of Business at the University of Michigan and a Bachelor of Engineering in Computer Engineering from the Thapar Institute of Engineering & Technology.

About USA Rare Earth

USA Rare Earth, Inc. (Nasdaq: USAR) is building a fully integrated rare earth and permanent magnet value chain across the United States, United Kingdom, and Europe. Through its ownership of Less Common Metals Ltd. (LCM) and development of magnet manufacturing capacity in Stillwater, Oklahoma, USA Rare Earth operates across the entire value chain – from heavy rare earth processing to metal-making, alloy production, and neodymium magnet manufacturing. By combining domestic feedstock from the Round Top deposit with advanced processing technologies, recycling capabilities, and an expanding European industrial footprint, USA Rare Earth is establishing a secure, sustainable, Western-aligned supply of materials essential to defense, electrification, robotics, energy, and advanced manufacturing.

Forward-Looking Statements

Certain statements made in this press release are or contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements, which involve risks and uncertainties, include statements regarding the Company’s future results of operations or financial condition, business strategies, and expectations for our business and industry. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. Words such as “accelerate,” “build,” “develop,” “drive,” “secure,” “position,” “will,” and similar  expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Detailed information regarding factors that may cause actual results to differ materially has been and will be included in the Companyʼs periodic filings with the SEC, including the Companyʼs Form 10-K that the Company filed with the SEC on March 30, 2026. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this Presentation speak only as of their date, and the Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances occurring after their date or to reflect the occurrence of unanticipated events.

Investor Relations Contact

JB Lowe
VP, Investor Relations
[email protected]

Media Relations Contact

Collected Strategies
[email protected]



KUSTOM ENTERTAINMENT AND CYCURION ANNOUNCE AGREEMENT ON TERMS FOR SALE OF LEGACY VIDEO SOLUTIONS SEGMENT

TARGET JUNE 30, 2026 CLOSING DATE

OVERLAND PARK, KS and MCLEAN, VA, April 17, 2026 (GLOBE NEWSWIRE) — Kustom Entertainment, Inc. (Nasdaq: KUST) (“Kustom” or the “Company”), and Cycurion, Inc. (Nasdaq: CYCU) today announced they have entered into a revised, non-binding Memorandum of Understanding (“MOU”) that establishes revised terms for the sale of Kustom’s legacy video solutions segment (the “Business”) to Cycurion from the previously announced MOU on January 22, 2026.

The parties have moved into the final stage of the transaction, focusing on the completion of definitive documentation. Based on the progress made to date, the parties currently anticipate the transaction will close on or prior to June 30, 2026.

Key Transaction Terms

Under the terms of the agreement, the aggregate purchase price is $5,500,000, structured to provide Kustom with immediate liquidity, long-term yield, and equity upside. The consideration consists of:

  • Cash Payment: A $1,250,000 cash down payment payable at closing.

  • Secured Promissory Note: A $4,250,000 secured promissory note bearing 7% interest, payable in 36 monthly installments.

  • Equity Upside: The issuance to Kustom of 2,000,000 common stock purchase warrants with a two-year term (beginning after the underlying shares become registered) and an exercise price of $2.80 per share.

  • Performance Adjustments: An earn-out and clawback mechanism, capped at $1,000,000, based on the Business achieving specific net income milestones, as defined in the definitive agreement, milestones over a one-year period for the clawback and a three-year period for the earn-out.

Strategic Comments

“We are pleased to have reached an agreement on the revised economic terms of this divestiture,” said Stanton Ross, CEO of Kustom. “This moves us into the final stretch of a transition that allows Kustom Entertainment to focus on its core growth initiatives while ensuring our legacy video customers continue to receive high-level service under Cycurion’s stewardship.”

“The acquisition of Kustom’s video solutions segment is a cornerstone of our portfolio expansion,” added L. Kevin Kelly, Chairman and CEO of Cycurion. “Our financial teams have worked closely to validate the pro forma outlook for this business, and we are eager to finalize the documentation and integrate these camera and software solutions into our broader technology offerings.”

Final Timeline and Documentation

The parties have agreed to a 30-day “no-shop” exclusivity period to facilitate the drafting of the final Asset Purchase Agreement. The transaction remains subject to the completion of definitive documentation, customary closing conditions, and any necessary regulatory approvals.

About Kustom Entertainment, Inc.

Kustom Entertainment, Inc. is a leader in live event production and ticketing technology, specializing in large-scale music festivals and end-to-end event management. Its flagship event, Country Stampede, is held annually at the Azura Amphitheater in Bonner Springs, Kansas.

The Company also maintains a legacy segment engaged in video solution technology (in-car and body-worn cameras) for law enforcement and security, currently integrating artificial intelligence to enhance its specialized product lines.

For additional information, please visit www.kustoment.com and www.digitalally.com.

About Cycurion, Inc.

Based in McLean, Virginia, Cycurion is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies LLC, Cloudburst Security LLC, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future. More info: www.cycurion.com.

Forward-Looking Statements

Statements made in this press release that are not descriptions of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on management’s current expectations and assumptions and are subject to risks and uncertainties including the ability of the parties to finalize definitive documentation and the satisfaction of closing conditions by the anticipated June 30, 2026 date.
Such statements include, but are not limited to, statements regarding the anticipated closing of the transactions contemplated by the MOU; the acceleration of the Company’s inorganic growth strategy; the integration of the Business; and other statements that are not historical facts, including statements which may be accompanied by words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. You should not place undue reliance on such forward-looking statements, which are based on the information currently available to us and speak only as of today’s date. All statements other than statements of historical fact are forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made, and the Company assumes no duty to update forward-looking statements, except as required by law. Examples of such risks and uncertainties include, but are not limited to, the outcomes of the parties’ investigations and Business integration, risks related to the closings of the transactions contemplated by the MOU, any potential legal proceedings, or the future performance of the Company’s stock. Actual future results, performance or achievements may differ materially from historical results or those anticipated depending on a variety of factors, some of which are beyond the control of the Company, including, but not limited to, the risks described from time to time in the Company’s periodic filings with the U.S. Securities and Exchange Commission, including, without limitation, the risks described in the Company’s 2025 Annual Report on Form 10-K under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (as applicable). These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. All information is current as of the date this press release is issued, and the Company undertakes no duty to update this information.

For Additional Information, Please Contact:

Kustom Entertainment: Stanton E. Ross, CEO at (913) 456-5878

Cycurion Investor Relations:(888) 341-6680 [email protected]

Cycurion Media Relations:(888) 341-6680 [email protected]



Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) — Upstream Bio, Inc.  (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in participants with CRSwNP and comorbid asthma, as well as its impact on nasal and blood biomarkers.

Presentation details:

  • Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, Administered in Participants with Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma in the VIBRANT Trial
    Presenting Author: Joseph K. Han, MD, Old Dominion University
    Poster Board Number: P1397
    Session: B32 – Rise of the Biologics: A New Hope for Breathing Easier
    Presentation Date and Time: Monday, May 18, 2026 – 11:30 AM – 1:15 PM ET
  • Presentation Title: Verekitug, a Thymic Stromal Lymphopoietin Receptor Antagonist, in Chronic Rhinosinusitis with Nasal Polyps: Effect on Type 2 Inflammatory Biomarkers in the VIBRANT Trial
    Presenting Author: Joseph K. Han, MD, Old Dominion University
    Poster Board Number: P1398
    Session: B32 – Rise of the Biologics: A New Hope for Breathing Easier
    Presentation Date and Time: Monday, May 18, 2026 – 11:30 AM – 1:15 PM ET

About Upstream Bio

Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist currently in clinical development that targets and inhibits the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. The Company has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit www.upstreambio.com.

Investor and Media Contact:

Meggan Buckwell
Director, Corporate Communications and Investor Relations
[email protected]



Polestar reports fourth quarter select and full-year 2025 financial results

Polestar reports fourth quarter select and full-year 2025 financial results

  • Record retail sales of 60,119 cars (+34% YoY); revenue surpassed USD 3 billion (+50% YoY)

  • Adjusted Gross Profit near breakeven; gross loss impacted by impairment expenses

  • Continued product cost, headcount and fixed cost reductions yielding meaningful savings

  • Improved capital structure profile and liquidity position

  • Cash position of approx. USD 1.2 billion as at 2025 year-end

  • 2026 guidance: low double-digit volume growth

GOTHENBURG, Sweden–(BUSINESS WIRE)–
Polestar (Nasdaq: PSNY) today presents its consolidated financial results and operational metrics for the year and three months ended December 31, 2025.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417910848/en/

Michael Lohscheller, Polestar CEO, said: “2025 was a record year for Polestar, with retail sales of over 60,000 cars and revenue surpassing USD 3 billion. Our strong commercial performance was driven by the expansion of our sales network and strength of our model line-up.

“Since June 2025 to-date, we have strengthened our balance sheet and improved our debt and liquidity positions through a total of USD 1.2 billion in equity injections, approx. USD 0.6 billion debt-to-equity conversions, partially executed and planned, and an agreement of a three-year extension of the USD 0.7 billion shareholder loan.

“In 2026, our operational focus will be on the continued expansion of our sales network, growing our sales points by a planned 20%, to coincide with the largest model offensive in our history, with four new models planned during the next three years. While we expect market conditions to become more challenging, amid ongoing geopolitical developments, we will continue to drive financial performance, building on our achievements in 2025, with an improved model mix, sustained cost reduction and financial discipline.”

Key financial and operational highlights for 2025 (year-on-year comparison)

  • Retail sales volumes up 34% driven by accelerated transition to an active selling model, retail expansion and attractive model line-up
  • Revenues up 50% to USD 3,058 million, driven by higher sales volumes
  • Gross margin of (35)% impacted by impairment expenses of approx. USD 1.1 billion
  • Adjusted gross loss of USD (22) million, significantly improved by USD 232 million
  • Selling, general and administrative expenses reduced year-on-year
  • Net loss of USD (2,357) million, mainly driven by impairment expense, net of reversals of approx. USD (1,050) million
  • Adjusted EBITDA loss of USD (783) million, an improvement of USD 297 million year-on-year
  • 2025 year-end cash position of USD 1,159 million

  • New equity of USD 0.5 billion raised from existing and external investors

Since the start of 2026

  • New equity of USD 0.7 billion raised from external investors
  • Debt-to-equity conversion of approx. USD 639 million of loans outstanding to Geely Sweden and Volvo Cars with USD 274 million already executed
  • Extension of maturity of Volvo Cars’ USD 726 million shareholder loan from December 2028 to December 2031

  • Largest model offensive in Polestar’s history: four new cars planned in three years (Polestar 5 in 2026, Polestar 4 new variant in 2026, Polestar 2 next generation in 2027 and Polestar 7 in 2028)
  • Intention to consolidate manufacturing of Polestar 3 in Charleston, South Carolina, USA to drive efficiencies

  • 2026 guidance with market conditions becoming more challenging, amid ongoing geopolitical developments: volume growth at low double-digit rate

Financial guidance

Polestar has continued to make major strides in its commercial transformation supported by accelerated retail expansion and the strength of its attractive model line-up in a challenging geopolitical and economic environment.

Looking to 2026, the global environment is expected to remain highly uncertain given recent geopolitical developments. As previously indicated, retail sales volumes are expected to increase at a low double-digit rate, with a continued focus on quality revenue. The sales mix is expected to further evolve with an increasing share of Polestar 4 coupe, our best-selling model, complemented later in 2026 with the introduction of new Polestar 4 SUV variant.

Key financial highlights

The table below summarizes key financial results for the 12 months ended December 31, 2025:

(in millions of U.S. dollars)

For the year ended

December 31,

 

 

2025

2024

Change, %

 

 

 

 

Revenue

3,058

 

2,034

 

50.3

 

Cost of sales

(4,142

)

(2,910

)

(42.3

)

Impairment expense, net of reversals

(1,050

)

(622

)

(68.8

)

Other cost of sales

(3,092

)

(2,288

)

(35.1

)

Gross loss

(1,084

)

(876

)

(23.7

)

Gross margin, %

(35.4

)

(43.1

)

7.7ppts

Adjusted Gross Loss (non-GAAP) 1

(22

)

(254

)

91.4

 

Adjusted Gross Margin (non-GAAP) 1, %

(0.7

)%

(12.5

)%

11.8ppts

Selling, general and administrative expense

(856

)

(891

)

3.8

 

Research and development expense

(78

)

(38

)

(102.4

)

Other operating income

52

 

59

 

(11.8

)

Other operating expense

(88

)

(24

)

(268.7

)

Foreign exchange gains (losses) on operating activities, net

44

 

(44

)

201.0

 

Operating loss

(2,009

)

(1,813

)

(10.8

)

Net loss

(2,357

)

(2,050

)

(15.0

)

Adjusted EBITDA (non-GAAP) 1

(783

)

(1,080

)

27.5

 

(1)

Non-GAAP measure. See Appendix C for details and a reconciliation of non-GAAP metrics to the nearest GAAP measure.

  • Retail sales totaled 60,119 cars, representing growth of 34.0% year-on-year (YoY) from 44,851 cars in the comparable period, driven by the transition to an active selling model, accelerated retail expansion and an attractive model line-up.

  • Revenue of USD 3,058 million, up by 50.3% from USD 2,034 million a year earlier, driven predominantly by higher volumes, a growing share of higher priced models (Polestar 3 and Polestar 4) in the sales mix, and carbon credits sales partially offset by pressure on pricing in a competitive and challenging market environment. Carbon credits sales totaled USD 211 million in the period from USD 11 million a year earlier, including USD 19 million worth of carbon credits sales booked in other operating income (2024: USD nil).

  • Cost of sales increased to USD (4,142) million, an increase of 42.3% from USD (2,910) million in 2024, mainly due to higher sales volumes and related increased production volumes and carline mix, as well as higher duties and tariffs related to increase in tariffs, primarily from China to the EU; higher cost of sales includes impairment expenses on tangible and intangible assets net of reversals of USD (1,050) million (2024: USD (622) million).

  • Gross margin was a negative (35.4)%, an improvement from (43.1)% in the comparable period, and includes impairment expenses booked in 2025.

  • Adjusted Gross Margin at near-breakeven of (0.7)%, an improvement from (12.5)% a year earlier; Adjusted Gross Loss significantly reduced to USD (22) million from USD (254) million in 2024 mainly as a result of evolving product and geographical sales mix, reduction in materials costs and higher carbon credits sales, lower adjustment of residual value guarantee in North American markets and positive impact from the China JV settlement partially offset by pressure on pricing and tariffs and collateral impact on inventory net realizable value.

  • Selling, General and Administrative (SG&A) expenses improved to USD (856) million from USD (891) million in 2024; expenses decreased by USD 100 million due to optimized marketing and advertising expenses, cost discipline and organizational restructuring with reduced headcount (from 2,547 in December 2024 to 1,686 in December 2025) but were partially offset by higher sales agent remuneration, by USD 65 million year-on-year, linked to growing retail sales volumes.

  • Research and development (R&D) expenses increased to USD (78) million from USD (38) million in the comparable period, driven by higher spend due to commencement of new programs with a lower capitalization rate.

  • Operating loss was USD (2,009) million compared to USD (1,813) million in 2024, primarily due to factors described above; other net operating income/expense was higher due to restructuring expenses related to headcount reduction and real-estate downsizing.

  • Net loss of USD (2,357) million, compared to net loss of USD (2,050) million in 2024, driven by factors described above; finance income was lower due to lower interest rates; finance expense was higher on higher levels of outstanding external financing; net foreign exchange gains on financial activities arose from positive FX movements; positive fair value changes from Earn-out rights and Class C shares were lower due to a smaller relative depreciation of Polestar’s share price over the period compared to prior year; share of losses in associates increased due to the capital contributions made by Polestar in its China associate in 2025 which triggered recognition of previously unrecognized losses.

  • Adjusted EBITDA of USD (783) million, improved by USD 297 million from USD (1,080) million in the comparable period, is a result of achieving near-breakeven Adjusted Gross Loss and optimizing SG&A expenses, which were partially offset by increased R&D expenses and higher sales agent remuneration.

  • Further details are provided in the reconciliation tables for non-GAAP measures in Appendix C.

Select results for Q4 2025

The table below summarizes key operational and financial results and provides the year-on-year (YoY) comparison for the three months ended December 31, 2026:

(in millions of U.S. dollars)

For the three months

ended December 31,

 

 

2025

2024

Change, %

 

 

 

 

Retail sales, units

15,608

12,256

27.3

 

 

 

 

Revenue

887

575

54.3

Gross Loss

(335)

(846)

60.4

Gross margin, %

(37.8)%

(147.1)%

109.3ppts

Adjusted Gross Profit / (Loss) (non-GAAP)1, %

17

(224)

nm

Adjusted Gross Margin (non-GAAP)1, %

1.9%

(39.0)%

40.9ppts

Net loss

(799)

(1,183)

32.5

Adjusted EBITDA (non-GAAP)1

(223)

(470)

52.6

(1)

Non-GAAP measure. See Appendix C for details and a reconciliation of non-GAAP metrics to the nearest GAAP measure.

For the three months ended December 31, 2025:

  • Retail sales totaled 15,608 cars, up 27.3% YoY from 12,256 cars a year earlier, supported by retail expansion and an attractive model line-up.

  • Revenue of USD 887 million, up by 54.3% from USD 575 million in the comparable period, driven predominantly by retail sales volumes and channel and product mix developments with a further positive contribution from carbon credits sales, lower residual value guarantee adjustment related to the North American markets and positive FX impact offset by pressure on pricing due to competitive and challenging pricing and market environment. Carbon credits sales totaled USD 88 million in the period from USD 11 million a year earlier, including USD nil million worth of carbon credits sales booked in other operating income (Q4 2024: USD nil million).

  • Gross margin at (37.8)%, an improvement of 109.3ppts from (147.1)% a year earlier, mainly due to lower impairment expenses of USD 340 million booked in the fourth quarter of 2025 compared to USD 622 million booked in the fourth quarter of 2024.

  • Adjusted Gross Margin turning positive at 1.9%, an improvement of 40.9ppts from (39.0)% in the comparable period, mainly due to favorable product and margin mix, especially due to Polestar 4 sales, higher carbon credits sales, and lower adjustment of residual value guarantee in North American markets partially offset by pressure on pricing and higher tariffs.

  • Net loss of USD (799) million, compared to net loss of USD (1,183) million for the fourth quarter of 2024, is better due to factors mentioned above and lower impairment expenses booked in Q4 2025.

  • Adjusted EBITDA loss of USD (223) million, compared to Adjusted EBITDA loss of USD (470) million for the fourth quarter of 2024, mainly due to improvement from Adjusted Gross Loss of USD (224) million in Q4 2024 to Adjusted Gross Profit of USD 17 million in Q4 2025.

Key operational highlights

The table below summarizes key operational results as of and for the 12 months and three months ended December 31, 2025:

 

For the year ended

December 31,

 

For the three months

ended December 31,

 

 

2025

2024

Change, %

2025

2024

Change, %

Retail sales 1

60,119

44,851

34.0

15,608

12,256

27.3

including external vehicles with repurchase obligations2

2,366

1,651

43.3

914

481

90.0

including internal vehicles

3,455

2,927

18.0

772

723

6.8

Markets3

28

27

+ 1 market

 

 

 

Sales points4

211

175

20.6

 

 

 

of which sales points, excluding China

211

140

50.7

 

 

 

Service points5

1,243

1,170

6.2

 

 

 

(1)

Retail sales figures are sales to end customers. Retail Sales include new cars handed over via all sales channels and all sale types, including but not restricted to internal, fleet, retail, rental and leaseholders’ channels across all markets irrespective of their market model and setup and may or may not generate directly revenue for Polestar.

(2)

In the year ended December 31, 2025 this number includes 179 cars that were handed over as security under a financing arrangement.

(3)

Represents the markets in which Polestar operates.

(4)

Represents Sales Points, including retail locations which are physical facilities (such as showrooms), actively selling Polestar cars, and pre-space activations, which represent locations with an ongoing project to build a retail location that have already started selling Polestar cars.

(5)

Represents Volvo Cars service centers to provide access to customer service points worldwide in support of Polestar’s international expansion.

  • Retail sales totaled 60,119 cars in the year ended December 31, 2025, representing growth of 34%, compared with 44,851 new cars sold in 2024, driven by the transition to an active selling model, accelerated retail expansion and an attractive model line-up.

  • Sales points, excluding China, grew at 51%. In 2025, Polestar opened 71 new retail sales points with a total of 211 sales points at the end of 2025. During 2025, Polestar signed up 54 new retailers with a total of 158 retail partners, representing an increase of 52%, at the end of 2025.

  • The increase in external sales with a repurchase obligation is primarily related to the delivery of Polestar 4 cars under a financing agreement in the German market.

  • Polestar increased sales of internal cars to support its retail network expansion.

Key cash flow highlights

The table below summarizes cash flow for the 12 months ended December 31, 2025:

(in millions of U.S. dollars)

For the year ended

December 31,

 

2025

Beginning cash

739

Operating

(915)

Investing

(521)

Financing

1,693

Foreign exchange effect on cash and cash equivalents

163

Ending cash

1,159

  • Operating cash outflow of USD (915) million, mainly driven by the operating loss net of non-cash adjustments, finance expenses and negative working capital movements due mainly to an increase in trade receivables due to high sales volumes in December and a decrease in trade payables offset by continuing inventory unwind.

  • Investing cash outflow of USD (521) million included additions to property, plant, and equipment as well as intangible assets and additions to investment in associates; investments were predominantly driven by investments in intellectual property and tangible assets related mainly to the model years of Polestar 3 and Polestar 4, Polestar 4 new variant, and to prepare for the commencement of production of Polestar 5 in Wuhan and Chongqing (China) in January 2026 as well the production of Polestar 4 in Busan (Korea) factory in H2 2025.

  • Financing cash inflow of USD 1,693 million, driven by net increase in proceeds from mainly short-term borrowing and, to a lesser extent, long-term borrowings and the new equity raises of a total of USD 500 million in June and December 2025. During the period, Polestar received a USD 200 million PIPE investment from PSD Investment Limited in June 2025 and USD 300 million investment from NATIXIS and BBVA in December 2025 as well as secured and renewed financing facilities.

  • Cash position of USD 1,159 million, compared to the 2024 year-end cash position of USD 739 million.

Key loan facilities and funding highlights

  • During 2025, approx. USD 4.6 billion of debt facilities were either renewed (approx. USD 3.0 billion) or newly secured (approx. USD 1.6 billion).

    • New facilities include previously announced secured term facilities of up to USD 450 million, EUR 150 million of term facilities, approx. CNY 2.8 billion in working capital facilities and USD 600 million in new Shareholder loan facility with Geely Sweden Holdings AB. This includes new facilities of USD 600 million secured in Q4 2025.

    • Renewed facilities include EUR 480 million for the renewed Green Trade Finance Facility (TFF), and approx. USD 2.4 billion of working capital facilities, of which CNY 3.0 billion was renewed in Q4 2025.

  • From June 2025 to March 2026, Polestar secured USD 1.2 billion of new equity:

    • Polestar secured a USD 200 million PIPE investment from PSD Investment Limited, an entity that is controlled by Mr. Shufu (Eric) Li, Founder and Chairman of Geely Holding Group, in June 2025.

    • In December 2025, Polestar secured USD 300 million from NATIXIS and BBVA.

    • In February 2026, Polestar secured USD 400 million from Feathertop Funding Limited, a special purpose vehicle consolidated to Sumitomo Mitsui Banking Corporation, and Standard Chartered Bank (Hong Kong) Limited.

    • In March 2026, Polestar secured USD 300 million from investors including Credit Agricole CIB, Vida France S.A., Innovator Limited and Proximaster Holdings Company.

  • In February 2026, Green Trade Finance Facility (TFF) with a syndicate of global banks restructured and renewed for EUR400 million. Additionally, approximately USD 570 million in working capital loans was renewed.

  • Geely Sweden and Volvo Cars agreed to convert approx. USD 639 million of loans outstanding to Polestar into equity with USD 274 million converted by Volvo Cars on March 31, 2026; Volvo Cars is expected to carry out a second debt-to-equity conversion later during the second quarter, totaling approximately USD 65 million.

  • On March 31, 2026, Volvo Cars extended the remaining USD 726 million shareholder loan to December 2031. Additionally, approximately USD 380 million in working capital loans was renewed.

  • Debt covenants and other covenants with Club Loan facility banks agreed and amended for test periods in 2025 and 2026.

The Company was in compliance with its covenants as of December 31, 2025.

The Company continues to have a constructive dialogue with lenders of the Company’s USD 950 million Club Loan regarding its future club loan obligations. On March 31, 2026, the Club Loan lenders agreed to amend the debt-to-asset ratio range for all test periods for 2026 as well as the minimum revenue covenant for 2026. Polestar complied with Club Loan covenants as of December 31, 2025.

In December 2025, Polestar, as borrower, entered into a credit agreement with a wholly owned subsidiary, as lender, of Geely Sweden Holdings AB in relation to a subordinated term loan facility of up to USD 600 million, of which the last USD 300 million would require lender consent based on Polestar’s future liquidity needs. The term loan facility is available to Polestar for general corporate purposes.

In February 2022, Polestar entered into an uncommitted TFF with a syndicate of leading global banks, to support its working capital requirements. The TFF was restructured and renewed for EUR400 million in February 2026.

Since December 2025, Polestar announced external equity investment of a total of USD 1 billion by institutional investors, including NATIXIS and BBVA, with USD 150 million each; Feathertop Funding Limited, a special purpose vehicle consolidated to Sumitomo Mitsui Banking Corporation, and Standard Chartered Bank (Hong Kong) Limited, with USD 200 million each; and Crédit Agricole CIB, Vida Finance S.A., Innovator Limited and Proximaster Holdings Company, with different amounts each. Concurrent with the purchase, these financial institutions have each entered into a put option arrangement with a wholly-owned subsidiary of Geely Sweden Holdings AB, which provides the financial institutions with an exit path, if needed, in three years with certain returns, as part of this equity financing arrangement. The price per Class A ADS to be purchased at each closing was USD 19.34. The financial institutions will not have any restrictions on the sale of the Class A ADSs they receive, subject to any applicable securities laws.

In conjunction with the equity financing in December 2025, Geely Sweden Holdings AB agreed with Polestar to convert approximately USD 300 million of its outstanding principal and interest owed by Polestar under a Term Facility Agreement, dated 8 November 2023, into equity at the conversion price of USD 19.34. The conversion is expected to be completed after the receipt of any necessary regulatory approvals.

On March 31, 2026, Volvo Cars converted approximately USD 274 million of its outstanding shareholder loan into Polestar’s equity, while also extending the maturity of the remaining USD 726 million shareholder loan to December 2031. Following completion of the previously announced approximate USD 300 million debt-to-equity conversion by Geely Sweden Holdings AB, Volvo Cars is expected to carry out a second debt-to-equity conversion later during the second quarter, totaling approximately USD 65 million. In doing so, Volvo Cars’ ownership in Polestar will remain at approximately 19.9%. The conversion price of USD 16.97 was set at 95 per cent of the 30-day volume-weighted average price in Polestar shares up to 27 March 2026.

With the support from Geely Holding Group, we have implemented significant steps to strengthen our balance sheet and improve our debt and liquidity positions, and we continue to consider new equity and debt funding.

ADS ratio change

On 9 December 2025, Polestar effected the ADS ratio change. Specifically, the Company’s Class A, Class B, Class C-1 and Class C-2 American Depositary Shares (collectively, the “ADSs”) ratio to the respective Class A, Class B, Class C-1 and Class C-2 ordinary shares (the “ADS Ratio”) changed from an ADS Ratio of one (1) ADS to one (1) ordinary share, to the a new ADS Ratio of one (1) ADS to thirty (30) ordinary shares.

Key recent developments and business highlights

  • Polestar commenced sales in France, its 28th market, in June 2025 with all three models available to order

  • Polestar 7, a premium compact SUV, was announced

  • Polestar 5 Grand Tourer revealed at IAA Mobility in Munich

  • Polestar publishes full Life Cycle Assessment for Polestar 5, strengthening industry-leading transparency

  • Polestar 4 achieves 5-star Euro NCAP safety rating

  • Polestar 4 wins the 2025 Mille Miglia Green

  • Polestar 4 receives Red Dot “Best of the Best” design award

  • Polestar 4 will be the first car to integrate Google Maps’ live lane guidance, winning the AutoBest Smartbest 2026 award

  • Polestar 3 introduces Abbey Rode Mode via over-the-air-update

  • Polestar 3 sets Guinness World Record for longest journey travelled by an electric SUV on a single charge

  • Polestar 3 upgraded with 800 Volt electrical architecture and peak DC charging rate of up to 350 kW for the 2026 model year

  • Polestar 3 named safest executive car of 2025

  • Polestar scales battery circularity by confirming up to 50% recycled cobalt in Polestar 2 and Polestar 3

  • Polestar announces Google Gemini to be introduced across model line-up via over-the-air updates

  • Polestar Charge now offers 1 million charge points through its partners

Calendar

Polestar expects to publish Q1 2026 select financial results on 7 May 2026 and host an audio call; further details will be available on Polestar’s Investor Relations website in due course.

Notes

All financial figures are in millions of U.S. dollars (USD). Unless otherwise stated, the performance shown in this press release covers the 12-month period to December 31, 2025 (FY 2025) and is compared to the 12-month period to December 31, 2024 (FY 2024) and the three-month period to December 31, 2025 (Q4 2025) and is compared to the three-month period to December 31, 2024 (Q4 2024).

About Polestar

Polestar (Nasdaq: PSNY) is the Swedish electric performance car brand with a focus on uncompromised design and innovation, and the ambition to accelerate the change towards a sustainable future. Headquartered in Gothenburg, Sweden, its cars are available in 28 markets globally across North America, Europe, and Asia Pacific.

Polestar has four models in its line-up: Polestar 2, Polestar 3, Polestar 4, and Polestar 5. Planned models include Polestar 4 new variant (to be introduced in the last quarter of 2026), Polestar 2 successor (to be launched early in 2027), Polestar 7 compact SUV (to be introduced in 2028) and the Polestar 6 roadster. With its vehicles currently manufactured on two continents, North America and Asia, Polestar is diversifying its manufacturing footprint further, with production of Polestar 7 planned in Europe.

Polestar has an unwavering commitment to sustainability and has set an ambitious roadmap to reach its climate targets: halve greenhouse gas emissions by 2030 per-vehicle-sold and become climate-neutral across its value chain by 2040. Polestar’s comprehensive sustainability strategy covers the four areas of Climate, Transparency, Circularity, and Inclusion.

Statement regarding unaudited financial and operational results

The unaudited financial and operational information published in this press release is subject to potential adjustments. Potential adjustments to operational and consolidated financial information may be identified from work performed during Polestar’s year-end audit. This could result in differences from the unaudited operational and financial information published herein. For the avoidance of doubt, the unaudited operational and financial information published in this press release should not be considered a substitute for the financial information filed with the SEC in Polestar’s Annual Reports on Form 20-F.

Forward-looking statements

Certain statements in this press release (“Press Release”) may be considered “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or the future financial or operating performance of Polestar including the number of vehicle deliveries and gross margin. For example, projections of revenue, volumes, margins, cash flow break-even and other financial or operating metrics and statements regarding expectations of future needs for funding and plans related thereto are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential”, “forecast”, “plan”, “seek”, “future”, “propose” or “continue”, or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward looking statements.

These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Polestar and its management, as the case may be, are inherently uncertain. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) Polestar’s ability to enter into or maintain agreements or partnerships with its strategic partners, including Volvo Cars and Geely, original equipment manufacturers, vendors and technology providers; (2) Polestar’s ability to maintain relationships with its existing suppliers, source new suppliers for its critical components and enter into longer term supply contracts and complete building out its supply chain; (3) Polestar’s ability to raise additional funding; (4) Polestar’s ability to successfully execute cost-cutting activities and strategic efficiency initiatives; (5) Polestar’s estimates of expenses, profitability, gross margin, cash flow, and cash reserves; (6) Polestar’s ability to continue to meet stock exchange listing standards; (7) changes in domestic and foreign business, market, financial, political and legal conditions; (8) demand for Polestar’s vehicles or car sale volumes, revenue and margin development based on pricing, variant and market mix, cost reduction efficiencies, logistics and growing aftersales; (9) delays in the expected timelines for the development, design, manufacture, launch and financing of Polestar’s vehicles and Polestar’s reliance on a limited number of vehicle models to generate revenues; (10) increases in costs, disruption of supply or shortage of materials, in particular for lithium-ion cells or semiconductors; (11) risks related to product recalls, regulatory fines and/or an unexpectedly high volume of warranty claims; (12) Polestar’s reliance on its partners to manufacture vehicles at a high volume, some of which have limited experience in producing electric vehicles, and on the allocation of sufficient production capacity to Polestar by its partners in order for Polestar to be able to increase its vehicle production volumes; (13) the ability of Polestar to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (14) risks related to future market adoption of Polestar’s offerings; (15) risks related to Polestar’s current distribution model and the evolution of its distribution model in the future; (16) the effects of competition and the high barriers to entry in the automotive industry and the pace and depth of electric vehicle adoption generally on Polestar’s future business; (17) changes in regulatory requirements (including environmental laws and regulations and regulations related to connected vehicles), governmental incentives, tariffs and fuel and energy prices; (18) Polestar’s reliance on the development of vehicle charging networks to provide charging solutions for its vehicles and its strategic partners for servicing its vehicles and their integrated software; (19) Polestar’s ability to establish its brand and capture additional market share, and the risks associated with negative press or reputational harm, including from electric vehicle fires; (20) the outcome of any potential litigation, including litigation involving Polestar and Gores Guggenheim, Inc., government and regulatory proceedings, including the NHTSA investigation into the Polestar 2 rear view camera, tax audits, investigations and inquiries; (21) Polestar’s ability to continuously and rapidly innovate, develop and market new products; (22) the impact of the ongoing conflict between Ukraine and Russia and the conflict with Iran and the conflict in the Red Sea; and (23) other risks and uncertainties set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in Polestar’s Form 20-F, and other documents filed, or to be filed, with the SEC by Polestar. There may be additional risks that Polestar presently does not know or that Polestar currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this Press Release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Polestar assumes no obligation to update these forward-looking statements, even if new information becomes available in the future, except as may be required by law.

Nothing in this Press Release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Polestar assumes no obligation to update these forward-looking statements, even if new information becomes available in the future, except as may be required by law.

Appendix A

Polestar Automotive Holding UK PLC

Consolidated Statement of Income (Loss)

(in millions of U.S. dollars unless otherwise stated)

 

 

For the year ended December 31,

 

2025

20241

Revenue

3,058

 

2,034

 

Cost of sales

(4,142

)

(2,910

)

Impairment expense, net of reversals

(1,050

)

(622

)

Other cost of sales

(3,092

)

(2,288

)

Gross loss

(1,084

)

(876

)

Selling, general and administrative expense

(856

)

(891

)

Research and development expense

(78

)

(38

)

Other operating income

52

 

59

 

Other operating expense

(88

)

(24

)

Foreign exchange gains (losses) on operating activities, net

44

 

(44

)

Operating loss

(2,009

)

(1,813

)

Finance income

9

 

24

 

Finance expense

(385

)

(341

)

Foreign exchange gains (losses) on financial activities, net

50

 

(53

)

Fair value changes – Earn-out rights and Class C shares

23

 

129

 

Share of losses in associates

(49

)

(5

)

Loss before income taxes

(2,361

)

(2,059

)

Income tax benefit

4

 

9

 

Net loss

(2,357

)

(2,050

)

(1)

Certain figures and descriptions were re-presented (see ‘Voluntary re-presentation from previous year’ in Note 2 – Material accounting policies and use of significant judgements and estimates in our Consolidated Financial Statements).

Polestar Automotive Holding UK PLC

Consolidated Statement of Financial Position

(in millions of U.S. dollars unless otherwise stated)

 

 

As of December 31,

 

2025

20241

Assets

 

 

Non-current assets

 

 

Intangible assets and goodwill

700

 

1,041

 

Property, plant and equipment

293

 

538

 

Vehicles under operating leases

101

 

56

 

Other assets

55

 

40

 

Deferred tax assets

92

 

82

 

Total non-current assets

1,241

 

1,756

 

Current assets

 

 

Cash and cash equivalents2

1,159

 

739

 

Trade receivables and other receivables

342

 

233

 

Inventories

853

 

1,079

 

Current tax assets

11

 

5

 

Other assets

323

 

242

 

Total current assets

2,689

 

2,298

 

Total assets

3,930

 

4,054

 

Equity

 

 

Share capital

(28

)

(21

)

Other contributed capital

(4,133

)

(3,625

)

Foreign currency translation reserve

15

 

63

 

Accumulated deficit

9,269

 

6,912

 

Total equity

5,122

 

3,329

 

Liabilities

 

 

Non-current liabilities

 

 

Contract liabilities

(76

)

(61

)

Deferred tax liabilities

(1

)

(1

)

Provisions

(134

)

(95

)

Other liabilities

(37

)

(71

)

Earn-out liability

(4

)

(29

)

Loans and borrowings

(2,499

)

(2,281

)

Lease liabilities

(94

)

(104

)

Total non-current liabilities

(2,844

)

(2,642

)

Current liabilities

 

 

Trade payables

(1,107

)

(894

)

Accrued expenses

(425

)

(520

)

Advance payments from customers

(16

)

(17

)

Provisions

(121

)

(73

)

Loans and borrowings

(3,861

)

(2,658

)

Current tax liabilities

(12

)

(29

)

Lease liabilities

(37

)

(31

)

Contract liabilities

(37

)

(38

)

Class C Shares liability

(5

)

(4

)

Other liabilities

(587

)

(478

)

Total current liabilities

(6,208

)

(4,741

)

Total liabilities

(9,052

)

(7,383

)

Total equity and liabilities

(3,930

)

(4,054

)

(1)

Certain figures and descriptions were re-presented (see ‘Voluntary re-presentation from previous year’ in Note 2 – Material accounting policies and use of significant judgements and estimates in our Consolidated Financial Statements).

(2)

Excludes restricted deposits.

Polestar Automotive Holding UK PLC

Consolidated Statement of Cash Flows

(in millions of U.S. dollars unless otherwise stated)

 

 

For the year ended December 31,

 

2025

2024

Cash flows from operating activities

 

 

Net loss

(2,357

)

(2,050

)

Adjustments to reconcile net loss to net cash flows:

 

 

Depreciation and amortization

53

 

56

 

Warranty provisions

89

 

35

 

Impairment of inventory (NRV)

156

 

90

 

Impairment of property, plant, and equipment, vehicles under operating leases, and intangible assets, net of reversals

1,050

 

622

 

Finance income

(9

)

(24

)

Finance expense

385

 

341

 

Fair value change – Earn-out rights and Class C Shares

(23

)

(129

)

Income tax benefit

(4

)

(9

)

Share of losses in associates

49

 

5

 

Net losses on derecognition and disposal of property, plant and equipment and intangible assets

31

 

6

 

Litigation provisions, net of insurance

3

 

(2

)

Other provisions

74

 

13

 

Exchange rate (income) loss, net

(66

)

62

 

Other non-cash expense and income

38

 

20

 

Changes in operating assets and liabilities:

 

 

Inventories

292

 

(255

)

Contract liabilities

2

 

(32

)

Trade and other receivables, prepaid expenses, and other assets

(134

)

85

 

Trade payables, accrued expenses, and other liabilities

(170

)

465

 

Restricted deposits

(25

)

(9

)

Interest received

9

 

21

 

Interest paid

(337

)

(293

)

Taxes paid

(21

)

(8

)

Cash used for operating activities

(915

)

(991

)

Cash flows from investing activities

 

 

Additions to property, plant, and equipment

(159

)

(148

)

Additions to intangible assets

(296

)

(209

)

Additions to investment in associates

(64

)

(34

)

Additions to other non-current assets

(7

)

(21

)

Proceeds from sale of property, plant and equipment

5

 

 

Cash used for investing activities

(521

)

(413

)

Cash flows from financing activities

 

 

Proceeds from short-term loans and borrowings

4,155

 

3,411

 

Proceeds from long-term loans and borrowings

191

 

938

 

Repayments of loans and borrowings

(3,117

)

(2,890

)

Proceeds from equity issuance

498

 

 

Proceeds from related party capital contribution

 

 

Repayments of lease liabilities

(34

)

(36

)

Cash provided by financing activities

1,693

 

1,424

 

Effect of foreign exchange rate changes on cash and cash equivalents

163

 

(49

)

Net increase (decrease) in cash and cash equivalents

420

 

(29

)

Cash and cash equivalents at the beginning of the period

739

 

768

 

Cash and cash equivalents at the end of the period

1,159

 

739

 

Appendix B

Impairment

  • For the impairment assessment, assets are grouped together into the smallest group of assets that generate cash inflows from continuing use that are largely independent of the cash inflows of other assets (i.e., a cash-generating-unit or CGU). For the years ended December 31, 2025 and 2024, Polestar had four lower-level cash generating units: (1) the Polestar 2, (2) the Polestar 3, (3) the Polestar 4, and (4) Internal Development Projects (IDP), mainly comprised of the Polestar 5, Polestar 6, and PX2 powertrain, as well as the Polestar Group level CGU.

  • For the year ended December 31, 2025, the recoverable amount for each CGU was based on their value in use and calculated based on estimations of future cash flows using assumptions that were generally consistent with the 2026-2030 business plan, adjusted where necessary to reflect changes in financial conditions and / or expectations in relation to the future subsequent to the preparation of that business plan. Mainly due to slower than expected industry-wide battery electric vehicles (BEV) adoption in the near term, lower demand in the electric vehicles upper premium segment, changes in regulations and policies and competitive dynamics, Polestar recognized additional impairment of USD 41 million, USD 891 million and USD 167 million on the Polestar 2, Polestar 3 and IDP CGU, respectively. As of December 31, 2025, the recoverable amount of the Polestar 2 CGU was USD (210) million, the recoverable amount of the Polestar 3 CGU was USD (190) million and the recoverable amount of the IDP CGU was USD 93 million.

Appendix C

Polestar Automotive Holding UK PLC

Non-GAAP Financial Measures

Polestar uses both generally accepted accounting principles (“GAAP,” i.e., IFRS) and non-GAAP (i.e., non-IFRS) financial measures to evaluate operating performance and for other strategic and financial decision-making purposes. Polestar believes non-GAAP financial measures are helpful to investors as they provide useful perspective on underlying business trends and assist in period-on-period comparisons. These measures also improve the ability of management and investors to assess and compare the financial performance and position of Polestar with those of other companies.

These non-GAAP measures are presented for supplemental information purposes only and should not be considered a substitute for financial information presented in accordance with GAAP. The measures are not presented under a comprehensive set of accounting rules and, therefore, should only be read in conjunction with financial information reported under GAAP when assessing Polestar’s operating performance.

The measures may not be the same as similarly titled measures used by other companies due to possible differences in calculation methods and items or events being adjusted. A reconciliation between non-GAAP financial measures and the most comparable GAAP performance measures is provided below.

Non-GAAP financial measures used by management are Adjusted EBITDA, Free Cash Flow, Adjusted Gross Profit / (Loss) and Adjusted Gross Margin.

Adjusted EBITDA is calculated as net loss, adjusted to exclude:

  • Fair value change – Earn-out rights and Class C Shares;

  • Finance expense;

  • Finance income;

  • Foreign exchange gains (losses) on financial activities, net;

  • Income tax benefit (expense);

  • Depreciation and amortization1;

  • Impairment of property, plant and equipment, vehicles under operating leases, and intangibles assets, net of reversals;

  • Gains (losses) on disposals of investments2;

  • Restructuring costs3; and

  • Unusual other operating income and expenses that are considered rare or discrete events and are infrequent in nature.

1 – Depreciation and amortization includes (a) depreciation and amortization capitalized into the carrying value of inventory sold (i.e., part of inventory costs) and (b) depreciation and amortization expense.

 

2 – Disposals of investments include disposals, by sales or otherwise, of: (a) debt or equity financial instruments issued by another entity that are held as investments, (b) intangible assets, (c) property, plant, and equipment, and (d) groups of assets and liabilities representing disposal groups that were transferred together as part of individual transactions.

 

3 – Restructuring costs include expenses associated with programs that were planned and controlled by management, and materially changed either (a) the scope of a business undertaken by the Group or (b) the manner in which business is conducted.

Management reviews this measure and believes it provides meaningful insight into the core business’s underlying operating performance and trends, before the effect of any adjusting items.

Free Cash Flow

Free Cash Flow is calculated as cash used for operating activities plus cash used to acquire property, plant and equipment and intangible assets. This measure is reviewed by management and management considers it to be a relevant measure for assessing cash generated by operating activities that are available to repay debts and spend on other strategic initiatives.

Adjusted Gross Profit / (Loss) and Adjusted Gross Margin

Adjusted Gross Profit / (Loss) is calculated as gross loss, adjusted to exclude: (i) expenses arising from the impairment of property, plant and equipment, vehicles under operating leases, and intangibles assets; and (ii) unusual other items of income or expense that are considered rare or discrete events and are infrequent in nature. Adjusted Gross Margin is calculated as Adjusted Gross Profit / (Loss) divided by revenue. These measures are reviewed by management and management considers them to be useful measures for assessing Polestar’s historical operating performance as they facilitate comparison between periods by excluding the non-cash impairment expense, the measurement of which includes significant assumptions related to future periods.

Reconciliation of Non-GAAP measures

Adjusted EBITDA

 

(in millions of U.S. dollars)

For the year ended December 31,

 

2025

2024

Net loss

(2,357

)

(2,050

)

Fair value change – Earn-out rights and Class C shares

(23

)

(129

)

Finance expense

385

 

341

 

Finance income

(9

)

(24

)

Foreign exchange (gains) losses on financial activities, net

(50

)

53

 

Income tax benefit

(4

)

(9

)

Depreciation and amortization

147

 

114

 

Impairment expense, net of reversals

1,050

 

622

 

Losses on disposals of investments

 

5

 

Restructuring costs

68

 

 

Unusual other operating income and expense, net2

11

 

(2

)

Adjusted EBITDA

(783

)

(1,080

)

1 – The Foreign exchange (gains) losses on financial activities, net were previously presented under Finance expense in the year ended December 31, 2024. Refer to Voluntary re-presentation from previous year in Note 2 – Material accounting policies and use of significant judgements and estimates) in the Consolidated Financial Statements for further information.

2 – For the year ended December 31, 2025, the amounts relate to: (i) $1,416 related to net gains of sale of PPE and intangibles; and (ii) $12,105 related to the battery recycling provision expense related to cars sold prior to 2025. For the year ended December 31, 2024 the amounts are related to the reduction in litigation provision, net of insurance.

Adjusted EBITDA
 

(in millions of U.S. dollars)

For the three months ended

December 31,

 

2025

2024

Adjusted EBITDA

 

 

Net loss

(799

)

(1,183

)

Fair value change – Earn-out rights and Class C shares

(4

)

(54

)

Finance expense

105

 

91

 

Finance income

(3

)

(13

)

Foreign exchange losses (gains) on financial activities, net

(5

)

42

 

Income tax benefit

43

 

(13

)

Depreciation and amortization

35

 

38

 

Impairment expense, net of reversals

338

 

622

 

Losses (gains) on disposals of investments

 

5

 

Restructuring costs

52

 

 

Unusual other operating income and expense, net

15

 

(4

)

Adjusted EBITDA

(223

)

(470

)

Adjusted Gross Profit / (Loss)

 

(in millions of U.S. dollars)

For the year ended December 31,

 

2025

2024

Gross loss

(1,084

)

(876

)

Impairment expense, net of reversals

1,050

 

622

 

Battery provision for cars sold prior to 20251

12

 

 

Adjusted Gross Profit / (Loss)

(22

)

(254

)

 

1 – In 2025, Polestar recognized a provision related to its obligations to recycle batteries in vehicles sold into certain markets, principally countries in the EU and the UK. The provision was recognized for all cars sold since Polestar began selling its BEV vehicles in 2021. This adjustment removes the amount of the provision expense related to the cars sold prior to 2025.

Adjusted Gross Profit / (Loss)

 

(in millions of U.S. dollars)

For the three months ended

December 31,

 

2025

2024

Gross loss

(335

)

(846

)

Impairment expense, net of reversals

340

 

622

 

Battery provision for cars sold prior to 20251

12

 

 

Adjusted Gross Profit / (Loss)

17

 

(224

)

 

1 – In 2025, Polestar recognized a provision related to its obligations to recycle batteries in vehicles sold into certain markets, principally countries in the EU and the UK. The provision was recognized for all cars sold since Polestar began selling its BEV vehicles in 2021. This adjustment removes the amount of the provision expense related to the cars sold prior to 2025.

Adjusted Gross Margin

 

(in millions of U.S. dollars)

For the year ended December 31,

 

2025

2024

Adjusted Gross Profit / (Loss) (a)

(22

)

(254

)

Revenue (b)

3,058

 

2,034

 

Adjusted Gross Margin (a/b)

(0.7

)%

(12.5

)%

Adjusted Gross Margin

 

(in millions of U.S. dollars)

For the three months ended

December 31,

 

2025

2024

Adjusted Gross Profit / (Loss) (a)

17

 

(224

)

Revenue (b)

887

 

575

 

Adjusted Gross Margin (a/b)

1.9

%

(39.0

)%

Free Cash Flow

 

(in millions of U.S. dollars)

For the year endedDecember 31,

 

2025

2024

Net cash used for operating activities

(915

)

(991

)

Additions to property, plant, and equipment

(159

)

(148

)

Additions to intangible assets

(296

)

(209

)

Free Cash Flow

(1,370

)

(1,348

)

 

Anna Gavrilova

Head of Investor Relations

[email protected]

Theo Kjellberg

Head of Corporate Communications

[email protected]

KEYWORDS: Sweden Europe

INDUSTRY KEYWORDS: Other Manufacturing Environment Alternative Vehicles/Fuels Automotive General Automotive Automotive Manufacturing Other Automotive Sustainability Manufacturing Green Technology

MEDIA:

Photo
Photo
Logo
Logo

HASI Announces First Quarter 2026 Earnings Release Date and Conference Call

HASI Announces First Quarter 2026 Earnings Release Date and Conference Call

ANNAPOLIS, Md.–(BUSINESS WIRE)–
HA Sustainable Infrastructure Capital, Inc. (“HASI,” “We”, “Our,” or the “Company”) (NYSE: HASI), a leading investor in sustainable infrastructure assets, today announced that the Company will release its first quarter 2026 results after market close on Thursday, May 7, 2026, to be followed by a conference call at 5:00 p.m. (Eastern Time).

The conference call can be accessed live over the phone by dialing 1-877-407-0890 (Toll-Free) or +1-201-389-0918 (toll). Participants should inform the operator they would like to join the “HASI First Quarter 2026 Results” call. The conference call will also be accessible as an audio webcast with slides, which interested investors and other parties may listen to by logging onto the Investor Relations section of the Company’s website at http://investors.hasi.com/. A replay after the event will be accessible for a limited time as an on-demand webcast on our website beginning immediately following the call.

To learn more about HASI, please visit the Company’s website at http://www.hasi.com. In addition to filing or furnishing required information to the U.S. Securities and Exchange Commission, HASI uses its website as a channel of distribution of material Company information. Financial and other material information regarding HASI is routinely posted on the Company’s website and is readily accessible.

About HASI

HASI is an investor in sustainable infrastructure assets advancing the energy transition. With more than $16 billion in managed assets, HASI’s investments are diversified across multiple asset classes, including utility-scale solar, storage, and onshore wind; distributed solar and storage; RNG; and energy efficiency. HASI combines deep expertise in energy markets and financial structuring with long-standing programmatic client partnerships to deliver superior risk-adjusted returns and measurable environmental benefits. HA Sustainable Infrastructure Capital, Inc. is listed on the New York Stock Exchange (Ticker: HASI). For more information, please visit hasi.com.

Aaron Chew

[email protected]

410-571-6189

KEYWORDS: Maryland United States North America

INDUSTRY KEYWORDS: Alternative Energy Energy Utilities Environment

MEDIA:

Logo
Logo

Pulse Biosciences to Host Analyst Event on April 25, 2026

Pulse Biosciences to Host Analyst Event on April 25, 2026

Management to discuss late-breaking data and the clinical program for its nPulse Cardiac Catheter System

HAYWARD, Calif.–(BUSINESS WIRE)–
Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on April 25, 2026, in Chicago, Illinois.

Management will highlight the late-breaking data from its European feasibility study for the treatment of atrial fibrillation and discuss its ongoing clinical program for the nPulse Cardiac Catheter system.

The Analyst Event will be held in hybrid format with a simultaneous online webcast. Those interested in attending in person are invited to reach out to register by contacting the investor relations department at [email protected]. Webcast attendees are encouraged to log on in advance of 12:45 PM CT on Saturday, April 25, 2026. A replay will also be available following the event on the ‘Events Calendar and Presentations’ page of the company’s investor website at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company’s proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue as well as initiating regulated cell death. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, nPulse, Vybrance, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Investor Contact:

Pulse Biosciences, Inc.

Jon Skinner, CFO

[email protected]

Or

Gilmartin Group

Philip Trip Taylor

415.937.5406

[email protected]

KEYWORDS: California Illinois United States North America

INDUSTRY KEYWORDS: Health Medical Devices Health Technology Research Science Pharmaceutical Biotechnology

MEDIA:

Logo
Logo